within Pharmacolibrary.Drugs.ATC.J;

model J05AE08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.24833333333333335,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.09670000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01983333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Atazanavir is an antiretroviral medication used in combination with other medications to treat and prevent HIV/AIDS. It is a protease inhibitor and is commonly administered orally. Atazanavir is approved by regulatory authorities such as the FDA and continues to be used clinically today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers at steady-state after oral administration of atazanavir 400 mg once daily, fasted state.</p><h4>References</h4><ol><li><p>Goldsmith, DR, &amp; Perry, CM (2003). Atazanavir. <i>Drugs</i> 63(16) 1679–1695. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363160-00003&quot;>10.2165/00003495-200363160-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12904086/&quot;>https://pubmed.ncbi.nlm.nih.gov/12904086</a></p></li><li><p>Krishna, G, et al., &amp; McLeod, J (2009). Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. <i>Journal of acquired immune deficiency syndromes (1999)</i> 51(4) 437–444. DOI:<a href=&quot;https://doi.org/10.1097/qai.0b013e3181acb51b&quot;>10.1097/qai.0b013e3181acb51b</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19623694/&quot;>https://pubmed.ncbi.nlm.nih.gov/19623694</a></p></li><li><p>Zhang, J, et al., &amp; Bertz, R (2011). The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. <i>Antiviral therapy</i> 16(2) 157–164. DOI:<a href=&quot;https://doi.org/10.3851/IMP1724&quot;>10.3851/IMP1724</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21447864/&quot;>https://pubmed.ncbi.nlm.nih.gov/21447864</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AE08;
